Thursday, October 23, 2014 5:32:05 PM
http://ih.advfn.com/p.php?pid=nmona&article=64154474&symbol=IBIO
The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against iBio, Inc. (NYSE: IBIO).
On October 9, 2014, the Washington Post reported that the manufacturer of the experimental Ebola drug ZMapp was seeking additional production capacity from Caliber Biotherapeutics (“Caliber”). On October 16, 2014, iBio issued a press release titled “iBio Responds to Inquiries About its Role in Emergency Response to Ebola Virus Disease Outbreak”, which (among other things) “confirmed [] the applicability of its issued U.S. iBio Launch platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus” and that it had been working with Caliber. iBio further “offered to assist the U.S. government by making its proprietary technology available [to] address the current Ebola virus outbreak”.
On October 17, 2014, it was announced that U.S. officials had asked the A&M Lab and two others to submit plans to produce the experimental Ebola drug ZMapp. Also on October 17, an iBio spokesperson was quoted as saying that any lab that wants to make ZMapp vaccine using plant-based technology would have to license it from iBio.
On October 20 and 23, 2014, reports were published online revealing that (a) iBio’s relationship with Caliber had nothing to do with an Ebola drug, (b) rival Icon Genetics AG had created a method to produce ZMapp using plant-based technology and need not license technology from iBio, and (c) the head of the A&M Lab had stated that any plant-based ZMapp manufacturing method would have to be identical to what the maker of the drug had already vetted in animals, ruling out different methods like iBio's.
On these adverse disclosures, iBio’s stock fell from $3.21 to $1.59, damaging investors.
As result of these adverse disclosures the Rosen Law Firm is preparing a securities class action on behalf of iBio shareholders. If you purchased iBio securities after October 10, 2014, please visit the website at http://www.rosenlegal.com/cases-409.html. You may also contact Phillip Kim, Esq., or Jonathan Horne, Esq., toll-free, at 866-767-3653; or by email at pkim@rosenlegal.com or jhorne@rosenlegal.com, for information on the class action.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
The Rosen Law Firm, P.A.
Laurence M. Rosen, Esq.
Phillip Kim, Esq.
Jonathan Horne, Esq.
275 Madison Avenue 34th Floor
New York, New York 10016
Tel: 212-686-1060
Toll Free: 1-866-767-3653
Fax: 212-202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
jhorne@rosenlegal.com
www.rosenlegal.com
Recent IBIO News
- iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- iBio Announces $15.0 Million Private Placement • GlobeNewswire Inc. • 03/26/2024 11:35:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:59:30 PM
- iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka • GlobeNewswire Inc. • 02/26/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:55:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:36:09 PM
- iBio Announces Participation in 23rd Annual PepTalk Conference • GlobeNewswire Inc. • 01/16/2024 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/10/2024 06:24:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:30:59 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/04/2024 01:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 12:44:38 PM
- iBio Amends and Extends Maturity of Credit Agreement • GlobeNewswire Inc. • 12/26/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:17:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 02:13:08 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/06/2023 01:59:51 PM
- iBio, Inc. Announces Pricing of $4.5 Million Public Offering • GlobeNewswire Inc. • 12/05/2023 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/05/2023 05:15:18 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/30/2023 01:55:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 01:36:43 PM
- iBio Announces Reverse Stock Split • GlobeNewswire Inc. • 11/27/2023 10:20:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:01:14 PM
- iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific • GlobeNewswire Inc. • 11/01/2023 12:24:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/27/2023 08:29:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/26/2023 12:20:58 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM